US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. 

The company's lead asset, brepocitinib, is a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL6, IL12, and IL23—with a single, targeted therapy. 

Brepocitinib has generated positive data in seven phase 2 studies with oral once-daily administration. It is currently being evaluated in a phase 3 program for dermatomyositis and is entering a phase 3 program for non-infectious uveitis.

This week on the podcast we have a conversation with Priovant’s CEO Benjamin Zimmer about dermatomyositis, non-infectious uveitis, current treatments, potential options, and how brepocitinib is making a difference. 

00:55-02:34 : About Priovant
02:34-06:38 : What are dermatomyositis and non-infectious uveitis?
06:38-08:35 : What are the current treatments?
08:35-12:32 : What is brepocitinib?
12:32-15:36 : Are there other treatments in development?
15:36-17:50 : What is your relationship with Pfizer?
17:50-20:48 : Brepocitinib clinical trials
20:48-24:06 : Future plans and timeline
24:06-27:59 : Finding patients for clinical trials
27:59-29:19 : Future opportunities
 
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter